Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02496065 · ClinicalTrials.gov registry record · Phase 1
Exploratory Study of Safety and ex Vivo Fluorescence of BLZ-100 in Adult Subjects With Solid Tumors Undergoing Surgery
A Phase 1 study, sponsored by Blaze Bioscience.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02496065 is a Phase 1 study that has completed, run by Blaze Bioscience. The registered enrollment target is 30 participants.
The verdict
NCT02496065, a Phase 1 study, has completed, sponsored by Blaze Bioscience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Surgery is the primary treatment modality for many types of cancer and the extent of surgical resection is directly related to patient survival. However, it is often difficult for surgeons to distinguish normal from neoplastic tissue or to detect metastatic disease or tumor-infiltrated lymph nodes. In some sites, surgical precision is also required to avoid damage to critical normal tissues. The purpose of this exploratory study is to evaluate the intra-operative and ex vivo fluorescence of BLZ-100 in tumor samples from subjects with breast cancer.
Interventions
- DRUG BLZ-100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-07 |
| Est. Completion | 2017-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02496065
The ClinicalTrials.gov registry entry for NCT02496065 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Blaze Bioscience, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BLZ-100 is the first listed.
NCT02496065 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02496065 about?
NCT02496065 is a clinical study titled "Exploratory Study of Safety and ex Vivo Fluorescence of BLZ-100 in Adult Subjects With Solid Tumors Undergoing Surgery". Surgery is the primary treatment modality for many types of cancer and the extent of surgical resection is directly related to patient survival. However, it is often difficult for surgeons to distinguish normal from neoplastic tissue or to detect metastatic disease or tumor-infiltrated lymph nodes. ...
What is the current status of trial NCT02496065?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2015-07. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02496065?
The interventions under investigation include: BLZ-100 (DRUG).
Who is sponsoring clinical trial NCT02496065?
This trial is sponsored by Blaze Bioscience, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.